Nøkkelinformasjon info chevron_right

Viktig informasjon i saken hentes i sanntid direkte fra EPO sitt register (European Patent Register), slik at du enkelt og raskt får oversikt i saken.
Beskrivelse Verdi
Saken / databasen er sist oppdatert info  
Tittel HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS
Status
Hovedstatus
Detaljstatus 		I kraft info EP patent gjort gjeldende i Norge EP patent besluttet gjeldende i Norge
Patentnummer NO/EP2854814
Europeisk (EP) publiserings nummer EP2854814
EP levert
EP søknadsnummer 13793417.0
EP meddelt
Avdelt til EP3338781;
Prioritet 2012.05.25, US 201261651669 P, .... se mer/flere nedenfor
Sakstype Europeisk
Løpedag
Utløpsdato
Allment tilgjengelig
Validert i Norge
Innehaver Corcept Therapeutics, Inc. (US)
Oppfinner HUNT, Hazel (GB) .... se mer/flere nedenfor
Fullmektig ZACCO NORWAY AS (NO)
Lenke til European patent Register Informasjon i saken, dokumenter og patentfamilie
Patentfamilie Se i Espacenet

Sammendrag og figur info chevron_right

EPO translation logo


Se forsidefigur og sammendrag i Espacenet

Beskrivelse og krav info chevron_right

T3

Beskrivelse

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (http://worldwide.espacenet.com) or via the search engine on our website here: https://search.patentstyret.no/

Krav

PATENTKRAV1. Forbindelse som har formelen:hvoriR1 er en heteroarylring som har fra 5 til 6 ringmedlemmer og fra 1 til 4 heteroatomer hver uavhengig valgt fra gruppen som består av N, O og S, eventuelt substituert med 1-4 grupper hver uavhengig valgt fra R1a;hver R1a er uavhengig valgt fra gruppen som består av hydrogen, C1-6alkyl, halogen, C1-6haloalkyl, C1-6alkoksy, C1-6haloalkoksy, -CN, N-oksid, C3-8sykloalkyl, og C3-8heterosykloalkyl;ring J er valgt fra gruppen som består av en sykloalkylring, en heterosykloalkylring, en arylring og en heteroarylring, hvori heterosykloalkyl- og heteroarylringene har fra 5 til 6 ringmedlemmer og fra 1 til 4 heteroatomer hver uavhengig valgt fra gruppen som består av N, O og S;hver R2 er uavhengig valgt fra gruppen som består av hydrogen, C1-6alkyl, halogen, C1-6haloalkyl, C1-6alkoksy, C1-6haloalkoksy, C1-6alkyl-C1-6alkoksy, -CN, -OH, -NR2aR2b, -C(O)R2a, -C(O)OR2a, -C(O)NR2aR2b, -SR2a, -S(O)R2a, -S(O)2R2a, C3-8sykloalkyl, og C3-8heterosykloalkyl, hvori heterosykloalkylgruppene eventuelt er substituert med 1-4 R2c-grupper;alternativt kombineres to R2-grupper knyttet til samme karbon for å danne en oksogruppe (=O);alternativt kombineres to R2-grupper for å danne en heterosykloalkylring som har fra 5 til 6 ringmedlemmer og fra 1 til 3 heteroatomer hver uavhengig valgt fra gruppen som består av N, O og S, hvori heterosykloalkylringen eventuelt er substituert med fra 1 til 3 R2d-grupper;R2a og R2b er hver uavhengig valgt fra gruppen som består av hydrogen og C1-6alkyl; hver R2c er uavhengig valgt fra gruppen som består av hydrogen, halogen, hydroksy, C1-6alkoksy, C1-6 haloalkoksy, -CN, og -NR2aR2b;hver R2d er uavhengig valgt fra gruppen som består av hydrogen og C1-6 alkyl, eller to R2d-grupper knyttet til det samme ringatomet kombineres for å danne (=O);R3 er valgt fra gruppen som består av fenyl og pyridyl, hver eventuelt substituert med 1-4 R3a-grupper;hver R3a er uavhengig valgt fra gruppen som består av hydrogen, halogen og C1-6haloalkyl;den senkede skriften n er et heltall fra 0 til 3;eller salter derav.2. Forbindelsen ifølge krav 1, hvoriR1 er en heteroarylring som har fra 5 til 6 ringmedlemmer og fra 1 til 4 heteroatomer hver uavhengig valgt fra gruppen som består av N, O og S, eventuelt substituert med 1-4 grupper hver uavhengig valgt fra R1a;hver R1a er uavhengig valgt fra gruppen som består av hydrogen, C1-6alkyl, halogen, C1-6haloalkyl, C1-6alkoksy, C1-6haloalkoksy, -CN, C3-8sykloalkyl, og C3-8heterosykloalkyl;ring J velges fra gruppen som består av en sykloalkylring, en heterosykloalkylring, en arylring og en heteroarylring, hvori heterosykloalkyl- og heteroarylringene har fra 5 til 6 ringmedlemmer og fra 1 til 3 heteroatomer hver uavhengig valgt gruppen som består av N, O og S;hver R2 er uavhengig valgt fra gruppen som består av hydrogen, C1-6alkyl, halogen, C1-6haloalkyl, C1-6alkoksy, C1-6haloalkoksy, -CN, NR2aR2b, C3-8sykloalkyl, og C3-8heterosykloalkyl, hvori heterosykloalkylgruppene eventuelt er substituert med 1-4 R2c-grupper;R2a og R2b er hver uavhengig valgt fra gruppen som består av hydrogen og C1-6alkyl;hver R2c er uavhengig valgt fra gruppen som består av hydrogen, halogen, hydroksy, C1-6alkoksy, C1-6haloalkoksy, -CN, og NR2aR2b;R3 er valgt fra gruppen som består av fenyl og pyridyl, hver eventuelt substituert med 1-4 R3a-grupper; hver R3a er uavhengig valgt fra gruppen som består av hydrogen, halogen, og C1-6haloalkyl; og den senkede skriften n er et heltall fra 0 til 3.3. Forbindelsen ifølge ett av kravene 1 til 2, hvori:(a) R1 er en heteroarylring som har fra 5 til 6 ringmedlemmer og fra 1 til 3 heteroatomer hver uavhengig valgt fra gruppen som består av N, O og S, eventuelt substituert med 1-4 grupper hver uavhengig valgt fra R1a;hver R1a er uavhengig valgt fra gruppen som består av hydrogen, C1-6alkyl, C1-6haloalkyl, og C1-6alkoksy;ring J er valgt fra gruppen som består av tetrahydrofuran, fenyl og pyridyl; hver R2 er uavhengig valgt fra gruppen som består av hydrogen, C1-6alkyl, halogen, C1-6haloalkyl, C1-6alkoksy, C1-6haloalkoksy, -CN, NR2aR2b, C3-8 sykloalkyl, og C3-8heterosykloalkyl;R2a og R2b er hver uavhengig valgt fra gruppen som består av hydrogen og C1-6alkyl;R3 er valgt fra gruppen som består av fenyl og pyridyl;R3a er F; ogden senkede skriften n er 0 eller 1; eller(b) R1 er en heteroarylring som har fra 5 til 6 ringmedlemmer og fra 1 til 3 heteroatomer hver uavhengig valgt fra gruppen som består av N, O og S, eventuelt substituert med 1-4 grupper hver uavhengig valgt fra R1a;hver R1a er uavhengig valgt fra gruppen som består av hydrogen, C1-6alkyl, C1-6haloalkyl, og C1-6alkoksy;ring J er valgt fra gruppen som består av fenyl og pyridyl;hver R2 er uavhengig valgt fra gruppen som består av hydrogen, halogen, C1-6haloalkyl, CN og C5-6heterosykloalkyl;R3 er valgt fra gruppen som består av fenyl og pyridyl; ogR3a er F.4. Forbindelsen ifølge ett av kravene 1 til 3, hvori R1 er valgt fra gruppen som består av(a) pyrrol, pyrazol, imidazol, triazol, tetrazol, furan, oksazol, isoksazol, oksadiazol, tiofen, tiazol, isotiazol, tiadiazol, pyridin, pyrazin, pyrimidin og pyridazin; (b) 2-pyrrol, 3-pyrrol, 3-pyrazol, 4-pyrazol, 5-pyrazol, 2-imidazol, 4-imidazol, 5-imidazol, 1,2,3-triazol-4-yl, 1,2,3-triazol-5-yl, 1,2,4-triazol-3-yl, 1,2,4-triazol-5-yl, 1,2,3,4-tetrazol-1-yl, 1,2,3,4-tetrazol-5-yl, 2-furan, 3-furan, 2-oksazol, 4-oksazol, 5-oksazol, 3-isoksazol, 4-isoksazol, 5-isoksazol, 1,2,4-oksadiazol-3-yl, 1,2,4-oksadiazol-5-yl, 1,2,5-oksadiazol-3-yl, 1,3,4-oksadiazol-2-yl, 2-tiofen, 3-tiofen, 2-tiazol, 4-tiazol, 5-tiazol, 3-isotiazol, 4-isotiazol, 5-isotiazol, 1,2,3-tiadiazol-4-yl, 1,2,3-tiadiazol-5-yl, 1,2,4-tiadiazol-3-yl, 1,2,4-tiadiazol-5-yl, 1,2,5-tiadiazol-3-yl, 1,3,4-tiadiazol-2-yl, 2-pyridin, 3-pyridin, 4-pyridin, pyrazin, 2-pyrimidin, 4-pyrimidin, 5-pyrimidin, 6-pyrimidin, 3-pyridazin, 4-pyridazin, 5-pyridazin, og 6-pyridazin;(c) pyrazol, imidazol, triazol, furan, oksazol, oksadiazol, tiofen, tiazol, pyridin, pyrazin og pyrimidin; eller(d) 1-pyrazol, 3-pyrazol, 4-pyrazol, 5-pyrazol, 2-imidazol, 4-imidazol, 5-imidazol, 1,2,3-triazol-4-yl, 1,2,3-triazol-5-yl, 1,2,4-triazol-3-yl, 1,2,4-triazol-5-yl, 2-furan, 3-furan, 2-oksazol, 4-oksazol, 5-oksazol, 1,2,4-oksadiazol-3-yl, 1,2,4-oksadiazol-5-yl, 1,2,5-oksadiazol-3-yl, 1,3,4-oksadiazol-2-yl, 2-tiofen, 3-tiofen, 2-tiazol, 4-tiazol, 5-tiazol, 2-pyridin, 3-pyridin, 4-pyridin, pyrazin, 2-pyrimidin, 4-pyrimidin, 5-pyrimidin og 6-pyrimidin.5. Forbindelsen ifølge ett av kravene 1, 2 og 4, hvori hver R1a er uavhengig valgt fra gruppen som består av hydrogen, C1-6alkyl, C1-6haloalkyl, C1-6alkoksy og C3-8heterosykloalkyl.6. Forbindelsen ifølge ett av kravene 1 til 5, hvori hver R1a er uavhengig valgt fra gruppen som består av hydrogen, metyl, etyl, trifluormetyl og metoksy.7. Forbindelsen ifølge ett av kravene 1, 2 og 4 til 6, hvori ring J er valgt fra gruppen som består av(a) heterosykloalkyl, aryl og heteroaryl;(b) aryl og heteroaryl; eller(c) fenyl, pyridin, imidazol, pyrazol, triazol, tetrazol, tiadiazol, isotiazol, isoksazol, sykloheksyl, tetrahydrofuran og tetrahydro-2H-pyran.8. Forbindelsen ifølge ett av kravene 1 til 7, hvori ring J er fenyl eller pyridyl.9. Forbindelsen ifølge ett av kravene 1 og 4 til 8, hvori hver R2 er uavhengig valgt fra gruppen som består av(a) hydrogen, C1-6alkyl, halogen, C1-6haloalkyl, C1-6alkoksy, C1-6haloalkoksy, C1-6alkyl-C1-6alkoksy, -CN, NR2aR2b, C(O)OR2a, S(O)2R2a, C3-8sykloalkyl, eller C3-8heterosykloalkyl, hvori heterosykloalkylgruppen har 5-6 ringmedlemmer og 1 til 2 heteroatomer; eller(b) hydrogen, metyl, etyl, propyl, isopropyl, F, Cl, -CF3, CH2OMe, OMe, OCHF2, -CN, -NMe2, -C(O)OH, -C(O)NMe2, -S(O)2Me, pyrrolidin, piperidin eller morfolin.10. Forbindelsen ifølge ett av kravene 1 til 9, hvori R3 er 4-F-fenyl.11. Forbindelsen ifølge krav 1, hvori forbindelsen er valgt fra gruppen som består av:(R)-(6-((6-klorpyridin-3-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(6-((6-klorpyridin-3-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(1-metyl-1H-imidazol-2-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-3-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(5-metyl-1,3,4-oksadiazol-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(oksazol-4-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(oksazol-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(furan-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(thiofen-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-(m-tolylsulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(oksazol-2-yl)metanon, (R)-(1-(4-fluorfenyl)-6-(m-tolylsulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyrimidin-2-yl)metanon,(R)-(6-((3,5-difluorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metoksypyridin-2-yl)metanon,(R)-(4-etylpyridin-2-yl)(1-(4-fluorfenyl)-6-((3,4,5-trifluorfenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((3,4,5-trifluorfenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metoksypyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((4-fluorfenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(6-((3-fluorbenzyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,((4aR)-1-(4-fluorfenyl)-6-((((R/S)-tetrahydrofuran-2-yl)metyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon, (R)-(1-(4-fluorfenyl)-6-(o-tolylsulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(6-((4-etylfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-(m-tolylsulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(6-((3-klorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((3-metoksyfenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(6-((4-klor-3-fluorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((4-metoksyfenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(6-((3-fluor-4-metylfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-(fenylsulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((2-fluorfenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((6-(trifluormetyl)pyridin-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-tosyl-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(6-((4-fluor-3-(trifluormetyl)fenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-4-((1-(4-fluorfenyl)-4a-pikolinoyl-4a,5,7,8-tetrahydro-1H-pyrazolo[3,4-g]isokinolin-6(4H)-yl)sulfonyl)benzonitril,(R)-(1-(4-fluorfenyl)-6-((6-metoksypyridin-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((tetrahydro-2H-pyran-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(6-(sykloheksylsulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(6-((-etyl-1H-pyrazol-5-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,(R)-(6-((3,5-dimetyl-1H-pyrazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,(R)-(6-((1H-imidazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((6-morfolinopyridin-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((6-(pyrrolidin-1-yl)pyridin-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((4-fluorfenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((3-fluorfenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,(R)-4-(((1-(4-fluorfenyl)-4a-(tiazol-2-karbonyl)-4a,5,7,8-tetrahydro-1H-pyrazolo[3,4-g]isokinolin-6(4H)-yl)sulfonyl)metyl)benzonitril,(R)-(1-(4-fluorfenyl)-6-((3-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(1-metyl-1H-1,2,4-triazol-5-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyrazin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((5-fluorpyridin-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((3-fluorfenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(5-metoksypyridin-2-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-5-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((5-fluorpyridin-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((4-(pyrrolidin-1-yl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((3-(pyrrolidin-1-yl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((5-(piperidin-1-yl)pyridin-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((5-(pyrrolidin-1-yl)pyridin-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((6-(pyrrolidin-1-yl)pyridin-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,((R)-1-(4-fluorfenyl)-6-((6-((R)-3-fluorpyrrolidin-1-yl)pyridin-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((4-(pyrrolidin-1-yl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((5-(piperidin-1-yl)pyridin-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((5-(pyrrolidin-1-yl)pyridin-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-4-yl)metanon,(R)-(6-((4-klorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((4-metoksy-3-metylfenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(6-((3-klor-4-metoksyfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(6-((3-fluor-4-metoksyfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(6-((2-fluor-4-metylfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-(m-tolylsulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-4-yl)metanon,(R)-3-((1-(4-fluorfenyl)-4a-pikolinoyl-4a,5,7,8-tetrahydro-lH-pyrazolo[3,4-g]isokinolin-6(4H)-yl)sulfonyl)benzonitril,(R)-(6-((4-(difluormetoksy)fenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((3-(trifluormetoksy)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(6-((3,5-difluorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-tosyl-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-4-yl)metanon,(R)-(6-((3-(difluormetoksy)fenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon, (R)-(6-((3,4-dimetylfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(6-((3,5-dimetylfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((6-metylpyridin-2-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(6-((3,4-difluorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((3,4,5-trifluorfenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(6-((3-klor-4-fluorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-3-((1-(4-fluorfenyl)-4a-(4-metylpikolinoyl)-4a,5,7,8-tetrahydro-1H-pyrazolo[3,4-g]isokinolin-6(4H)-yl)sulfonyl)benzonitril,(R)-(1-(4-fluorfenyl)-6-((1-metyl-1-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon, (R)-(6-((3,4-difluorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-imidazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon, (R)-(6-((3,5-difluorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((3,4,5-trifluorfenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((3-(metylsulfonyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-3-((1-(4-fluorfenyl)-4a-pikolinoyl-4a,5,7,8-tetrahydro-1H-pyrazolo[3,4-g]isokinolin-6(4H)-yl)sulfonyl)benzosyre,(R)-(1-(4-fluorfenyl)-6-((3-(metoksymetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((4-metyl-3,4-dihydro-2H-pyrido[3,2-b][1,4]oksazin-7-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((2,3,4-trifluorfenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((6-(trifluormetyl)pyridin-2-yl)sulfonyl)-4,4a,5 ,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((6-(trifluormetyl)pyridin-2-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon, (R)-(6-((3,4-diklorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((3-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon, (R)-(6-((1-etyl-1H-pyrazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon, (R)-(6-((1,5-dimetyl-1H-pyrazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-pyrazol-5-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-pyrazol-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon, (R)-(6-((4-fluor-3-metylfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((4-metyl-3,4-dihydro-2H-pyrido[3,2-b][1,4]oksazin-7-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,(R)-(6-((2,3-dihydrobenzofuran-5-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon, (R)-5-((1-(4-fluorfenyl)-4a-(4-metylpikolinoyl)-4a,5,7,8-tetrahydro-1H-pyrazolo[3,4-g]isokinolin-6(4H)-yl)sulfonyl)-1-metylindolin-2-on,(R)-(1-(4-fluorfenyl)-6-((3-(metylsulfonyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon, (R)-(6-((1,3-dimetyl-1H-pyrazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon, (R)-(6-((2,3-dihydrobenzo[b][1,4]dioksin-6-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,(R)-(6-((3-fluor-4-(trifluormetyl)fenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon, (R)-(6-((3-fluor-4-(trifluormetyl)fenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-3-((4a-(4-etylpikolinoyl)-1-(4-fluorfenyl)-4a,5,7,8-tetrahydro-1H-pyrazolo[3,4-g]isokinolin-6(4H)-yl)sulfonyl)benzonitril,(R)-(4-etylpyridin-2-yl)(1-(4-fluorfenyl)-6-((6-(trifluormetyl)pyridin-2-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)metanon, (R)-3-((1-(4-fluorfenyl)-4a-(4-metylpikolinoyl)-4a,5,7,8-tetrahydro-1H-pyrazolo[3,4-g]isokinolin-6(4H)-yl)sulfonyl)benzosyre,(R)-(6-((3,5-dimetylisoksazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon, (R)-(6-((1-etyl-1H-pyrazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(1-fenyl-6-((3-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(6-((1,3-dimetyl-1H-pyrazol-5-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((2-(trifluormetyl)pyridin-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)pyridin-2-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((5-metyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((2-(trifluormetyl)pyridin-4-yl)sulfonyl)-4,4a,5 ,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(6-((4-klor-3-(trifluormetyl)fenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(6-((3-klor-4-metylfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon, (R)-(6-((3,4-difluorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(2-(pyrrolidin-1-yl)pyridin-4-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-pyrazol-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-pyrazol-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((5-metyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,(R)-3-((1-(4-fluorfenyl)-4a-(4-(trifluormetyl)pikolinoyl)-4a,5,7,8-tetrahydro-1H-pyrazolo[3,4-g]isokinolin-6(4H)-yl)sulfonyl)benzonitril,(R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-pyrazol-5-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,(R)-(6-((1,5-dimetyl-1H-pyrazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,(R)-(6-((1H-pyrazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((1-metyl-3-(trifluormetyl)-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((3,4,5-trifluorfenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,(R)-(1-(4-klorfenyl)-6-((1-metyl-1H-pyrazol-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,(R)-(6-((1H-pyrazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(6-((1-metyl-1H-pyrazol-3-yl)sulfonyl)-1-(4-(trifluormetyl)fenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon, (R)-(6-((3,4-difluorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-4-yl)metanon, (R)-(6-((1,2-dimetyl-1H-imidazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,(R)-(6-((1,2-dimetyl-1H-imidazol-5-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-imidazol-2-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,(R)-(6-((1-etyl-1H-imidazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,(R)-(6-((1-etyl-1H-pyrazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-4-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((1-propyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((1-(2-metoksyetyl)-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon, (R)-(6-((3,4-diklorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(1-metyl-1H-pyrazol-4-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((1-isopropyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((2-metyl-2H-1,2,3-triazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-1,2,3-triazol-5-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-1,2,3-triazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,(R)-(6-((2-etyl-2H-1,2,3-triazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon, (R)-(6-((1-etyl-1H-1,2,3-triazol-5-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(6-((1-etyl-1H-1,2,3-triazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(6-((2-etyl-2H-1,2,3-triazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,(R)-(6-((1-etyl-1H-1,2,3-triazol-5-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,(R)-(6-((1-etyl-1H-1,2,3-triazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((2-propyl-2H-1,2,3-triazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((1-propyl-1H-1,2,3-triazol-5-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((1-propyl-1H-1,2,3-triazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((2-propyl-2H-1,2,3-triazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-4-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((1-propyl-1H-1,2,3-triazol-5-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-4-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((1-propyl-1H-1,2,3-triazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-4-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((2-isopropyl-2H-1,2,3-triazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((1-isopropyl-1H-1,2,3-triazol-5-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((1-isopropyl-1H-1,2,3-triazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon, (R)-(6-((1-etyl-1H-pyrazol-5-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-4-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((1-propyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-4-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((1-propyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-4-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((3-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-(m-tolylsulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((3-metoksyfenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,(R)-(6-((3-fluor-4-metylfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-(fenylsulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,(R)-(6-((3-klorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,(R)-(1(4-fluorfenyl)-6-(m-tolylsulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(5-metylpyridin-2-yl)metanon,(R)-(1-4-fluorfenyl)-6-(m-tolylsulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-(m-tolylsulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(6-metylpyridin-2-yl)metanon,(R)-(6-((4-fluor-3-(trifluormetyl)fenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((3,4,5-trifluorfenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,(R)-(6-((3-fluor-4-(trifluormetyl)fenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((3-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(5-metyltiazol-2-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((3-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metyltiazol-2-yl)metanon, (R)-(6-((3,4-diklorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,(R)-(6-((3,4-diklorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(5-metyltiazol-2-yl)metanon,(R)-(6-((3,4-difluorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,(R)-(6-((3,4-difluorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(5-metyltiazol-2-yl)metanon,(R)-(6-((4-klor-3-fluorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(5-metyltiazol-2-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-pyrazol-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(5-metyltiazol-2-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(5-metyltiazol-2-yl)metanon, (R)-(6-((1,3-dimetyl-1H-pyrazol-5-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(5-metyltiazol-2-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-pyrazol-5-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(5-metyltiazol-2-yl)metanon, (R)-(6-((1-etyl-1H-pyrazol-5-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,(R)-(6-((1-etyl-1H-pyrazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((1-propyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-tosyl-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(1-metyl-1H-imidazol-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-(m-tolylsulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo [3,4-g]isokinolin-4a-yl)(1-metyl-1H-imidazol-2-yl)metanon ,(R)-3-((1-(4-fluorfenyl)-4a-pikolinoyl-4a,5,7,8-tetrahydro-1H-pyrazolo[3,4-g]isokinolin-6(4H)-yl)sulfonyl)-N,N-dimetylbenzamid, (R)-(6-((1-etyl-1H-pyrazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,(R)-pyridin-2-yl(1-(pyridin-3-yl)-6-((3-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)metanon,(R)-(6-((3,4-diklorfenyl)sulfonyl)-1-fenyl-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(6-((3,4-diklorfenyl)sulfonyl)-1-(3,4-difluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(6-((3,5-difluor-4-metoksyfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(6-((6-(dimetylamino)pyridin-3-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-5-((1-(4-fluorfenyl)-4a-pikolinoyl-4a,5,7,8-tetrahydro-1H-pyrazolo[3,4-g]isokinolin-6(4H)-yl)sulfonyl)-1-metylpyridin-2(1H)-on,(R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon, og(R)-(6-((3,4-diklorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-4-yl)metanon, eller salter derav.12. Forbindelsen ifølge krav 1, hvori forbindelsen er valgt fra gruppen som består av:(R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,(R)-(6-((3,4-difluorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(6-((3,4-diklorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon, (R)-(6-((3,4-diklorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,(R)-(6-((3,4-diklorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(5-metyltiazol-2-yl)metanon,(R)-(6-((3-fluor-4-(trifluormetyl)fenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon ,(R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-pyrazol-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-pyrazol-5-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,(R)-(6-((1-etyl-1H-pyrazol-5-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon, eller(R)-(6-((3,4-diklorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-4-yl)metanon.13. Farmasøytisk sammensetning som omfatter en forbindelse ifølge ett av kravene 1 til 12 og en farmasøytisk akseptabel eksipiens, som eventuelt ytterligere omfatter et antiinflammatorisk glukokortikosteroid.14. Forbindelse ifølge ett av kravene 1 til 12 for anvendelse i en fremgangsmåte for behandling av inflammatoriske sykdommer, autoimmune sykdommer og/eller kreft, hvori fremgangsmåten omfatter modulering av en glukokortikoidreseptor som omfatter å bringe glukokortikoidreseptoren i kontakt med forbindelsen.15. Forbindelse ifølge ett av kravene 1 til 12 for anvendelse i en fremgangsmåte for behandling av en forstyrrelse valgt fra gruppen som består av fedme, diabetes, kardiovaskulær sykdom, hypertensjon, syndrom X, depresjon, angst, glaukom, humant immundefektvirus (HIV) eller ervervet immundefektssyndrom (AIDS), nevrodegenerasjon, Alzheimers sykdom, Parkinsons sykdom, kognisjonsforbedring, Cushings syndrom, Addisons sykdom, osteoporose, skjørhet, muskelsvikt, inflammatoriske sykdommer, slitasjegikt, revmatoid artritt, astma og rhinitt, adrenalfunksjonsrelaterte plager, virusinfeksjon, immundefekt, immunmodulering, autoimmune sykdommer, allergier, sårheling, tvangsmessig adferd, multilegemiddelmotstand, avhengighet, psykose, anoreksi, kakeksi, posttraumatisk stressyndrom, postkirurgisk beinfraktur, medisinsk katabolisme, større psykotisk depresjon, mild kognitiv svekkelse, psykose, demens, hyperglykemi, stressforstyrrelser, antipsykotisk indusert vektøkning, delirium, kognitiv forringelse hos individer med Downs syndrom, psykose forbundet med interferon-alfa-behandling, kronisk smerte, smerte assosiert med gastroøsofageal reflukssykdom, postpartumpsykose, postpartumdepresjon, nevrologiske forstyrrelser hos premature spedbarn og migrenehodepine; gjennom antagonisering av en glukokortikoidreseptor, idet fremgangsmåten omfatter å administrere en terapeutisk effektiv mengde av forbindelsen til et individ som har behov for det, for derved å behandle forstyrrelsen.
Hva betyr A1, B, B1, C osv? info

Klasser info chevron_right

Innehaver(e) info chevron_right

Innehaver i EP:
Corcept Therapeutics, Inc.
149 Commonwealth Drive Menlo Park CA 94025 US

Oppfinner(e) info chevron_right

HUNT, Hazel
Edenderry House Bracken Close Storrington West Sussex GB
JOHNSON, Tony
8/9 Spire Green Centre Flex Meadow Harlow Essex GB
RAY, Nicholas
8/9 Spire Green Centre Flex Meadow Harlow Essex GB
WALTERS, Iain
BioCity Pennyfoot Street Nottingham NG1 1GF GB

Fullmektig info chevron_right

Fullmektig i Norge:
ZACCO NORWAY AS
Postboks 488 0213 OSLO NO ( OSLO kommune, Oslo fylke )

Org.nummer: 982702887
Din referanse: P61800697NO00E
  • Foretaksnavn:
  • Foretaksform:
  • Næring:
  • Forretningsadresse:
     

Kilde: Brønnøysundregistrene
Fullmektig i EP:
J A Kemp LLP
80 Turnmill Street London EC1M 5QU GB

Prioritet info chevron_right

2012.05.25, US 201261651669 P

2012.08.20, US 201261691083 P

2012.10.19, US 201261715907 P

2013.02.01, US 201361759520 P

2013.03.14, US 201361781629 P

Anførte dokumenter info chevron_right

US-A- 4 963 558 (B1)

US-A1- 2007 281 928 (B1)

WO-A1-2012/027702 (B1)

US-A1- 2011 166 110 (B1)

WO-A1-2005/087769 (B1)

US-A1- 2010 179 115 (B1)

Sakshistorikk info chevron_right

Statushistorie

Liste over statusendringer i sakshistorikk
Hovedstatus Beslutningsdato, detaljstatus
EP patent gjort gjeldende i Norge EP patent besluttet gjeldende i Norge
EP under behandling Forespørsel om å gjøre EP patent gyldig er mottatt

Korrespondanse

expand_more file_download  
Liste over sakshistorikk og korrespondanse
Dato Type korrespondanse Journal beskrivelse
Innkommende EP Publiseringsdokument fra EPO
20-01 EP Publiseringsdokument fra EPO EP Publiseringsdokument fra EPO
Innkommende EP Publiseringsdokument fra EPO
19-01 EP Publiseringsdokument fra EPO EP Publiseringsdokument fra EPO
Innkommende EP Publiseringsdokument fra EPO
18-01 EP Publiseringsdokument fra EPO EP Publiseringsdokument fra EPO
Innkommende EP Publiseringsdokument fra EPO
17-01 EP Publiseringsdokument fra EPO EP Publiseringsdokument fra EPO
Innkommende EP Publiseringsdokument fra EPO
16-01 EP Publiseringsdokument fra EPO EP Publiseringsdokument fra EPO
Innkommende EP Publiseringsdokument fra EPO
15-01 EP Publiseringsdokument fra EPO EP Publiseringsdokument fra EPO
Innkommende EP Publiseringsdokument fra EPO
14-01 EP Publiseringsdokument fra EPO EP Publiseringsdokument fra EPO
Innkommende EP Publiseringsdokument fra EPO
13-01 EP Publiseringsdokument fra EPO EP Publiseringsdokument fra EPO
Innkommende EP Publiseringsdokument fra EPO
12-01 EP Publiseringsdokument fra EPO EP Publiseringsdokument fra EPO
Innkommende EP Publiseringsdokument fra EPO
11-01 EP Publiseringsdokument fra EPO EP Publiseringsdokument fra EPO
Innkommende EP Publiseringsdokument fra EPO
10-01 EP Publiseringsdokument fra EPO EP Publiseringsdokument fra EPO
Innkommende EP Publiseringsdokument fra EPO
09-01 EP Publiseringsdokument fra EPO EP Publiseringsdokument fra EPO
Innkommende EP Publiseringsdokument fra EPO
08-01 EP Publiseringsdokument fra EPO EP Publiseringsdokument fra EPO
Innkommende EP Publiseringsdokument fra EPO
07-01 EP Publiseringsdokument fra EPO EP Publiseringsdokument fra EPO
Innkommende EP Publiseringsdokument fra EPO
06-01 EP Publiseringsdokument fra EPO EP Publiseringsdokument fra EPO
Innkommende EP Publiseringsdokument fra EPO
05-01 EP Publiseringsdokument fra EPO EP Publiseringsdokument fra EPO
Utgående EP Registreringsbrev (3210)
04-01 Brev UT EP Registreringsbrev (3210)
Utgående EP Batch Varsel om betaling av første årsavgift (3319)
03-01 Via Altinn-sending EP Batch Varsel om betaling av første årsavgift (3319)
Innkommende Søknadsskjema Patent
01-01 Søknadsskjema Patent Søknadsskjema Patent
01-02 EP oversettelse EP krav
01-03 Fullmakt Fullmakt
01-04 Hovedbrev EP søknadsskjema
Innkommende EP Publiseringsdokument fra EPO
02-01 EP Publiseringsdokument fra EPO EP Publiseringsdokument fra EPO
Informasjon om ikke tilgjengelige dokumenter

Betaling info chevron_right

Til betaling:

Beskrivelse Forfallsdato Beløp Status
Årsavgift expand_less Ikke betalt
Årsavgift 13. avg. år (EP) 5460,0 Totalbeløp 5460,0   Gå til betaling

Betalingshistorikk:

Liste av betalinger
Beskrivelse / Fakturanummer Betalingsdato Beløp Betaler Status
Årsavgift 12. avg. år (EP) 2024.05.08 5010 CPA GLOBAL LIMITED Betalt og godkjent
Årsavgift 11. avg. år (EP) 2023.05.10 3500 CPA GLOBAL LIMITED Betalt og godkjent
Årsavgift 10. avg. år (EP) 2022.05.10 3200 CPA GLOBAL LIMITED Betalt og godkjent
Årsavgift 9. avg. år (EP) 2021.05.11 2850 CPA GLOBAL LIMITED Betalt og godkjent
Årsavgift 8. avg. år (EP) 2020.05.11 2550 CPA GLOBAL LIMITED Betalt og godkjent
Årsavgift 7. avg. år (EP) 2019.05.09 2200 CPA GLOBAL LIMITED Betalt og godkjent
Årsavgift 6. avg. år (EP) 2018.05.09 2000 CPA GLOBAL LIMITED Betalt og godkjent
31806237 expand_more 2018.04.25 5500 ZACCO NORWAY AS Betalt
Denne oversikten kan mangle informasjon, spesielt for eldre saker, om tilbakebetaling, internasjonale varemerker og internasjonale design.

Publikasjon(er) info chevron_right

Lenker til publikasjoner og Norsk Patenttidende (søkbare tekstdokumenter)

Oversettelse av europeisk patentskrift
Allment tilgjengelig patentsøknad
Norsk Patenttidende - ved meddelelse
Nye digitale Norske Tidende, nyhet om tjenesten ved lansering
Om Norske Tidende
Hva betyr A1, B, B1, C osv? info
Kapitler uten data er fjernet. Melding opprettet: 27.04.2025 08:06:04